- Home
- ANTA vs KLRS Comparison
ANTA vs KLRS Comparison
Compare ANTA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTA | KLRS |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5M | 113.0M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANTA | KLRS |
|---|---|---|
| Price | $3.58 | $4.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $16.17 | ★ $19.00 |
| AVG Volume (30 Days) | 4.5K | ★ 613.4K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | $21.95 | N/A |
| Revenue Next Year | $30.46 | N/A |
| P/E Ratio | $19.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.00 | $2.36 |
| 52 Week High | $13.82 | $11.88 |
Technical Indicators
Market Signals| Indicator | ANTA | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 50.76 |
| Support Level | $3.00 | $3.96 |
| Resistance Level | $4.17 | $4.40 |
| Average True Range (ATR) | 0.31 | 0.31 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 49.57 | 78.10 |
Price Performance
Historical ComparisonAbout ANTA Antalpha Platform Holding Company Ordinary Shares
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.